NIH R01 · 2024
Hypertension, Inflammation, and Vascular Function
PROJECT SUMMARY Preeclampsia (PE) is estimated to affect 5-7% of all pregnancies in the U.S. The initiating event in PE is postulated to involve reduced placental perfusion that leads to widespread chronic immune activation and maternal vascular dysfunction. Despite its position as a leading cause of maternal death and major contributor to maternal and perinatal morbidity, there is no effective drug treatment to prevent preeclampsia, and current management therapies have significant limitations. At present, the only effective treatment for preeclampsia is early delivery of the baby and placenta. Based on recent studies and on preliminary data presented in this application, we propose that…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.